{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:15:45Z","timestamp":1791260145334,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["#63526947"],"award-info":[{"award-number":["#63526947"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Isavuconazole is an antifungal drug used for treatment of invasive fungal infections. Critically ill COVID-19 and influenza patients require extracorporeal membrane oxygenation (ECMO) in cases with severe acute respiratory distress syndrome and have risk factors for invasive pulmonary aspergillosis. Little is known about isavuconazole plasma concentrations during ECMO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine isavuconazole plasma concentrations in seven patients treated with intravenous isavuconazole under ECMO and the influence of the ECMO circuit immediately after the first isavuconazole dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Critically ill patients treated with isavuconazole (standard doses) and ECMO were included in this study. Sixty-four blood samples used for measurement of isavuconazole concentrations were collected at several timepoints starting 2\u2005h after the first isavuconazole dose up to 168\u2005h. An additional 27 blood samples were drawn from the inflow and outflow line of the membrane oxygenator to assess any potential isavuconazole clearance effect of the ECMO oxygenation device and the lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median isavuconazole trough levels above 1\u2005\u03bcg\/mL (min. 0.83, max. 1.73) or 2\u2005\u03bcg\/mL (min. 0.84, max. 2.97) were achieved 24\u2005h or 96\u2005h after the first dose of isavuconazole. The isavuconazole plasma concentrations pre (inflow line) and post (outflow line) the membrane oxygenator were directly correlated (\u03c1\u200a=\u200a0.987, R2\u200a=\u200a0.994, P\u200a&amp;lt;\u200a0.001). Post membrane oxygenator isavuconazole concentrations were directly correlated to contemporaneous samples obtained from the arterial lines of patients (\u03c1\u200a=\u200a0.942, R2\u200a=\u200a0.945, P\u200a&amp;lt;\u200a0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Isavuconazole concentrations might be influenced by the higher volume of distribution due to ECMO therapy, but were not altered by the ECMO oxygenator and achieved median plasma concentrations &amp;gt;1\u2005\u03bcg\/mL 24\u2005h after the first loading dose.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkac196","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T02:10:47Z","timestamp":1655777447000},"page":"2500-2505","source":"Crossref","is-referenced-by-count":43,"title":["Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation"],"prefix":"10.1093","volume":"77","author":[{"given":"Lisa","family":"Kriegl","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hatzl","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-0360","authenticated-orcid":false,"given":"Christoph","family":"Zurl","sequence":"additional","affiliation":[{"name":"Division of General Paediatrics, Department of Paediatrics and Adolescent Medicine, Medical University of Graz , Graz , Austria"},{"name":"BioTechMed-Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Christian","family":"Reisinger","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Schilcher","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Eller","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Gringschl","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Muhr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Landeskrankenhaus Graz 2 , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meinitzer","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Prattes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz , Austria"},{"name":"BioTechMed-Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Krause","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz , Graz , Austria"},{"name":"BioTechMed-Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"2022082518384703800_dkac196-B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022082518384703800_dkac196-B2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2022082518384703800_dkac196-B3","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022082518384703800_dkac196-B4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2022082518384703800_dkac196-B5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022082518384703800_dkac196-B6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13054-021-03753-9","article-title":"Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study","volume":"25","author":"Hatzl","year":"2021","journal-title":"Crit Care"},{"key":"2022082518384703800_dkac196-B7","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3201\/eid2711.211174","article-title":"Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis","volume":"27","author":"Janssen","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2022082518384703800_dkac196-B8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","article-title":"Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology","volume":"28","author":"Prattes","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022082518384703800_dkac196-B9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study","volume":"10","author":"Gangneux","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2022082518384703800_dkac196-B10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384703800_dkac196-B11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: Outcome, tolerability and clinical implications of isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2022082518384703800_dkac196-B12","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.21037\/jtd.2017.09.154","article-title":"Optimising drug dosing in patients receiving extracorporeal membrane oxygenation","volume":"10","author":"Cheng","year":"2018","journal-title":"J Thorac Dis"},{"key":"2022082518384703800_dkac196-B13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2022082518384703800_dkac196-B14","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/microorganisms9071543","article-title":"A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation","volume":"9","author":"Van Daele","year":"2021","journal-title":"Microorganisms"},{"key":"2022082518384703800_dkac196-B15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"Verweij","year":"2021","journal-title":"Intensive Care Med"},{"key":"2022082518384703800_dkac196-B16","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022082518384703800_dkac196-B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2022082518384703800_dkac196-B18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"key":"2022082518384703800_dkac196-B19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022082518384703800_dkac196-B20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/FTD.0000000000000632","article-title":"Interlaboratory analysis of isavuconazole plasma concentration assays among European laboratories","volume":"41","author":"Pea","year":"2019","journal-title":"Ther Drug Monit"},{"key":"2022082518384703800_dkac196-B21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0041-1730755","article-title":"Implementation of a dual-column liquid chromatography-tandem Mass-spectrometry method for the quantification of isavuconazole in clinical practice","volume":"13","author":"Enko","year":"2021","journal-title":"J Lab Physicians"},{"key":"2022082518384703800_dkac196-B22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2022082518384703800_dkac196-B23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/jof7090726","article-title":"Influenza-associated disseminated aspergillosis in a 9-year-old girl requiring ECMO support","volume":"7","author":"Mendoza-Palomar","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2022082518384703800_dkac196-B24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/phar.2348","article-title":"Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation","volume":"40","author":"Zhao","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2022082518384703800_dkac196-B25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13054-017-1644-y","article-title":"Medicating patients during extracorporeal membrane oxygenation: the evidence is building","volume":"21","author":"Dzierba","year":"2017","journal-title":"Crit Care"},{"key":"2022082518384703800_dkac196-B26","author":"(EMA) EMA","year":"2015"},{"key":"2022082518384703800_dkac196-B27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384703800_dkac196-B28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/jac\/dkab012","article-title":"Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"76","author":"Van Daele","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384703800_dkac196-B29","doi-asserted-by":"crossref","first-page":"ofw172.1498","DOI":"10.1093\/ofid\/ofw172.1498","article-title":"No dose adjustment necessary for isavuconazole in obese patients","volume":"3","author":"Desai","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2022082518384703800_dkac196-B30","doi-asserted-by":"crossref","first-page":"e01034-17","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082518384703800_dkac196-B31","article-title":"Triazole antifungal therapeutic drug monitoring","author":"Lewis"},{"key":"2022082518384703800_dkac196-B32","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384703800_dkac196-B33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dky463","article-title":"Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases","volume":"74","author":"Kaindl","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022082518384703800_dkac196-B34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/mmy\/myaa022","article-title":"Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center","volume":"58","author":"Borman","year":"2020","journal-title":"Med Mycol"},{"key":"2022082518384703800_dkac196-B35","doi-asserted-by":"crossref","first-page":"e01634-18","DOI":"10.1128\/AAC.01634-18","article-title":"Outcomes by MIC values for patients treated with isavuconazole or voriconazole for invasive aspergillosis in the phase 3 SECURE and VITAL trials","volume":"63","author":"Andes","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/9\/2500\/45536581\/dkac196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/9\/2500\/45536581\/dkac196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T13:04:03Z","timestamp":1700744643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/9\/2500\/6611931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,21]]},"published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac196","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,21]]}}}